Focusing on advanced kidney cancer, medical oncologists offer clinical perspectives on treatment in the second line and beyond.
Fruquintinib Combo Prolongs PFS in Advanced/Metastatic RCC
Data from the FRUSICA-2 trial may support fruquintinib/sintilimab as a “valuable” option for patients with advanced renal cell carcinoma.
Key Advances Across Kidney Cancer Research and Management at KCRS 2025
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.
Benmelstobart Combo Elicits PFS Advantage in Untreated Advanced ccRCC
Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.
Unveiling Advances in GU Cancers: Insights from Oncology Decoded
Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.
Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC
Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.
Pembrolizumab/Axitinib Improves Survival vs Sunitinib in Advanced RCC
The biomarker analysis in KEYNOTE-426 showed that pembrolizumab plus axitinib therapy is associated with positive outcomes with angiogenesis in RCC.